高盟新材(300200.SZ)午後一度直線拉昇逼近漲停 持有國內光刻膠龍頭北京科華股權
格隆匯2月18日丨市場普遍認為二期半導體基金會傾向於半導體產業鏈的薄弱環節,比如高端光刻膠等會受到更多二期資金的傾斜。
今日光刻膠概念股全線大漲,午間在互動平台上稱持有國內光刻膠龍頭北京科華股權的高盟新材(300200.SZ)午後一度直線拉昇逼近漲停,現報12.61元,漲6.77%,暫成交1.66億元,最新總市值33.6億元。

公司午間在互動平台上表示,目前持有北京科華微電子材料有限公司3.6698%股權,北京科華是國內光刻膠龍頭企業,並已經為中芯國際供貨。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.